Published in Neurobiol Dis on December 22, 2016
NIH Image to ImageJ: 25 years of image analysis. Nat Methods (2012) 84.41
Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol (2008) 15.90
Mechanisms underlying inflammation in neurodegeneration. Cell (2010) 7.66
NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev (2012) 5.77
The general transcription machinery and general cofactors. Crit Rev Biochem Mol Biol (2006) 5.52
Inflammation in neurodegenerative disease--a double-edged sword. Neuron (2002) 4.95
NF-kappa B functions in synaptic signaling and behavior. Nat Neurosci (2003) 3.40
Innate immunity: the missing link in neuroprotection and neurodegeneration? Nat Rev Neurosci (2002) 2.97
A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J Exp Med (2008) 2.78
Roles for NF-kappaB in nerve cell survival, plasticity, and disease. Cell Death Differ (2006) 2.67
Glial reactions in Parkinson's disease. Mov Disord (2008) 2.62
Inhibiting NF-κB activation by small molecules as a therapeutic strategy. Biochim Biophys Acta (2010) 2.55
The complement system: an unexpected role in synaptic pruning during development and disease. Annu Rev Neurosci (2012) 2.53
Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol (2008) 2.46
Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol (2007) 2.36
Inhibitors of NF-kappaB signaling: 785 and counting. Oncogene (2006) 2.33
Early and progressive accumulation of reactive microglia in the Huntington disease brain. J Neuropathol Exp Neurol (2001) 2.17
The E3 ligase parkin maintains mitochondrial integrity by increasing linear ubiquitination of NEMO. Mol Cell (2013) 2.12
Phosphorylation of parkin by Parkinson disease-linked kinase PINK1 activates parkin E3 ligase function and NF-kappaB signaling. Hum Mol Genet (2009) 2.10
Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. Proc Natl Acad Sci U S A (1997) 1.99
Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease. Exp Mol Med (2006) 1.94
Divergent gene regulation and growth effects by NF-kappa B in epithelial and mesenchymal cells of human skin. Oncogene (2003) 1.93
Microglial activation in presymptomatic Huntington's disease gene carriers. Brain (2007) 1.93
NF-kappaB activity in transgenic mice: developmental regulation and tissue specificity. Development (1996) 1.89
Inflammatory process in Parkinson's disease: role for cytokines. Curr Pharm Des (2005) 1.87
LRRK2 is involved in the IFN-gamma response and host response to pathogens. J Immunol (2010) 1.85
Physiological functions for brain NF-kappaB. Trends Neurosci (2005) 1.85
Functional anatomy of the basal ganglia in X-linked recessive dystonia-parkinsonism. Ann Neurol (2005) 1.70
NF-kappaB in the nervous system. Cold Spring Harb Perspect Biol (2009) 1.70
Activation of the IkappaB kinase complex and nuclear factor-kappaB contributes to mutant huntingtin neurotoxicity. J Neurosci (2004) 1.64
Signaling via NF-kappaB in the nervous system. Biochim Biophys Acta (2005) 1.63
Reduced neuron-specific expression of the TAF1 gene is associated with X-linked dystonia-parkinsonism. Am J Hum Genet (2007) 1.62
LRRK2 inhibition attenuates microglial inflammatory responses. J Neurosci (2012) 1.61
Molecular mechanisms of interleukin-10-mediated inhibition of NF-kappaB activity: a role for p50. Clin Exp Immunol (2004) 1.56
Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat Commun (2013) 1.55
Parkin mediates neuroprotection through activation of IkappaB kinase/nuclear factor-kappaB signaling. J Neurosci (2007) 1.54
Interaction of the COOH-terminal transactivation domain of p65 NF-kappa B with TATA-binding protein, transcription factor IIB, and coactivators. J Biol Chem (1995) 1.53
Defects in the striatal neuropeptide Y system in X-linked dystonia-parkinsonism. Brain (2013) 1.53
Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of action. Biochem Pharmacol (2010) 1.52
Leucine-rich repeat kinase 2 positively regulates inflammation and down-regulates NF-κB p50 signaling in cultured microglia cells. J Neuroinflammation (2015) 1.50
Phosphorylation on Thr-55 by TAF1 mediates degradation of p53: a role for TAF1 in cell G1 progression. Mol Cell (2004) 1.44
Torsion dystonia in Panay, Philippines. Adv Neurol (1976) 1.35
Differential regulation of NF-kappaB by elongation factors is determined by core promoter type. Mol Cell Biol (2007) 1.33
Toll-like receptor 4 is required for α-synuclein dependent activation of microglia and astroglia. Glia (2012) 1.32
Neuronal life-and-death signaling, apoptosis, and neurodegenerative disorders. Antioxid Redox Signal (2006) 1.29
Structural insights into transcription initiation by RNA polymerase II. Trends Biochem Sci (2013) 1.27
Transcription factor NF-kappaB is transported to the nucleus via cytoplasmic dynein/dynactin motor complex in hippocampal neurons. PLoS One (2007) 1.26
Specific sequence changes in multiple transcript system DYT3 are associated with X-linked dystonia parkinsonism. Proc Natl Acad Sci U S A (2003) 1.26
p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain. Neurosci Lett (2006) 1.24
Impaired inflammatory responses in murine Lrrk2-knockdown brain microglia. PLoS One (2012) 1.21
A requirement for nuclear factor-kappaB in developmental and plasticity-associated synaptogenesis. J Neurosci (2011) 1.19
Refined linkage disequilibrium and physical mapping of the gene locus for X-linked dystonia-parkinsonism (DYT3). Genomics (1999) 1.19
Involvement of TFIID and USA components in transcriptional activation of the human immunodeficiency virus promoter by NF-kappaB and Sp1. Mol Cell Biol (1998) 1.19
TAFII105 mediates activation of anti-apoptotic genes by NF-kappaB. EMBO J (1998) 1.15
New insights into the function of transcription factor TFIID from recent structural studies. Curr Opin Genet Dev (2011) 1.15
Real-time monitoring of nuclear factor kappaB activity in cultured cells and in animal models. Mol Imaging (2009) 1.13
HTT-lowering reverses Huntington's disease immune dysfunction caused by NFκB pathway dysregulation. Brain (2014) 1.13
Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein. Exp Neurol (2012) 1.10
Stimulated nuclear translocation of NF-kappaB and shuttling differentially depend on dynein and the dynactin complex. Proc Natl Acad Sci U S A (2009) 1.08
A critical role of astrocyte-mediated nuclear factor-κB-dependent inflammation in Huntington's disease. Hum Mol Genet (2013) 1.07
Regulation of NF-κB by TNF family cytokines. Semin Immunol (2014) 1.06
Dystonia-parkinsonism syndrome (XDP) locus: flanking markers in Xq12-q21.1. Am J Hum Genet (1992) 1.04
Inhibition of Thr-55 phosphorylation restores p53 nuclear localization and sensitizes cancer cells to DNA damage. Proc Natl Acad Sci U S A (2008) 1.02
The phenotype of the X-linked dystonia-parkinsonism syndrome. An assessment of 42 cases in the Philippines. Medicine (Baltimore) (1991) 1.01
Neuropathology of lubag (x-linked dystonia parkinsonism). Mov Disord (1993) 1.01
Assignment of the dystonia-parkinsonism syndrome locus, DYT3, to a small region within a 1.8-Mb YAC contig of Xq13.1. Am J Hum Genet (1995) 0.99
Signaling via the NFκB system. Wiley Interdiscip Rev Syst Biol Med (2016) 0.98
The Huntington's disease mutation impairs Huntingtin's role in the transport of NF-κB from the synapse to the nucleus. Hum Mol Genet (2010) 0.97
NF-kappaB Signaling Pathways in Neurological Inflammation: A Mini Review. Front Mol Neurosci (2015) 0.94
The natural history of sex-linked recessive dystonia parkinsonism of Panay, Philippines (XDP). Parkinsonism Relat Disord (2002) 0.93
DXS106 and DXS559 flank the X-linked dystonia-parkinsonism syndrome locus (DYT3). Genomics (1994) 0.93
Activation and control of CNS innate immune responses in health and diseases: a balancing act finely tuned by neuroimmune regulators (NIReg). CNS Neurol Disord Drug Targets (2011) 0.93
Enhanced apoptosis of B and T lymphocytes in TAFII105 dominant-negative transgenic mice is linked to nuclear factor-kappa B. J Biol Chem (2002) 0.93
Interaction of TAFII105 with selected p65/RelA dimers is associated with activation of subset of NF-kappa B genes. J Biol Chem (2000) 0.92
Genetic mapping of "Lubag" (X-linked dystonia-parkinsonism) in a Filipino kindred to the pericentromeric region of the X chromosome. Ann Neurol (1991) 0.92
Synaptic NF-kappa B pathway in neuronal plasticity and memory. J Physiol Paris (2014) 0.92
High-resolution structure of TBP with TAF1 reveals anchoring patterns in transcriptional regulation. Nat Struct Mol Biol (2013) 0.90
DJ-1 enhances cell survival through the binding of Cezanne, a negative regulator of NF-kappaB. J Biol Chem (2010) 0.90
The unique phenomenology of sex-linked dystonia parkinsonism (XDP, DYT3, "Lubag"). Int J Neurosci (2010) 0.90
NF-κB: emerging roles in hippocampal development and function. Int J Biochem Cell Biol (2013) 0.88
Activation of MyD88-dependent TLR1/2 signaling by misfolded α-synuclein, a protein linked to neurodegenerative disorders. Sci Signal (2015) 0.87
TAF1 differentially enhances androgen receptor transcriptional activity via its N-terminal kinase and ubiquitin-activating and -conjugating domains. Mol Endocrinol (2010) 0.85
Roles for NF-κB and gene targets of NF-κB in synaptic plasticity, memory, and navigation. Mol Neurobiol (2013) 0.85
Leucine-rich repeat kinase 2 modulates cyclooxygenase 2 and the inflammatory response in idiopathic and genetic Parkinson's disease. Neurobiol Aging (2013) 0.84
Nonmotor features in sex-linked dystonia parkinsonism. Neurodegener Dis Manag (2014) 0.84
Reactive oxygen species, redox signaling and neuroinflammation in Alzheimer's disease: the NF-κB connection. Curr Top Med Chem (2015) 0.84
Significance of NF-κB as a pivotal therapeutic target in the neurodegenerative pathologies of Alzheimer's disease and multiple sclerosis. Expert Opin Ther Targets (2015) 0.84
X-linked dystonia ("Lubag") presenting predominantly with parkinsonism: a more benign phenotype? Mov Disord (2002) 0.84
The X-linked dystonia-parkinsonism syndrome (XDP): clinical and molecular genetic analysis. Brain Pathol (1992) 0.84
New insights into the genetics of X-linked dystonia-parkinsonism (XDP, DYT3). Eur J Hum Genet (2015) 0.82
Understanding XDP through imaging, pathology, and genetics. Int J Neurosci (2010) 0.82
Structural bioinformatics of the general transcription factor TFIID. Biochimie (2012) 0.81
Structural and functional analysis of the human TAF1/DYT3 multiple transcript system. Mamm Genome (2007) 0.81
Novel NF-κB inhibitors: a patent review (2011 - 2014). Expert Opin Ther Pat (2015) 0.81
The promise of deep brain stimulation in X-linked dystonia parkinsonism. Int J Neurosci (2011) 0.80
PINK1 stimulates interleukin-1β-mediated inflammatory signaling via the positive regulation of TRAF6 and TAK1. Cell Mol Life Sci (2012) 0.80
Phenomenology of "Lubag" or X-linked dystonia-parkinsonism. Mov Disord (2002) 0.80
Phenotypic and molecular analyses of X-linked dystonia-parkinsonism ("lubag") in women. Arch Neurol (2004) 0.79
Phosphorylation of p53 by TAF1 inactivates p53-dependent transcription in the DNA damage response. Mol Cell (2013) 0.79
Evidence of TAF1 dysfunction in peripheral models of X-linked dystonia-parkinsonism. Cell Mol Life Sci (2016) 0.76